Bright Mind Shares Surge 91% After Reporting Positive EEG Clinical Results Of Next-Gen Compound
Portfolio Pulse from Lara Goldstein
Bright Minds Bioscience (NASDAQ:DRUG) announced positive results from its quantitative EEG study, causing its stock to surge 91%. The Phase 1 study showed positive data regarding BMB-101's safety and tolerability profile. The compound demonstrated central target engagement and predictable plasma pharmacokinetics. The company plans to apply with the FDA to advance to Phase 2.
August 08, 2023 | 4:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bright Minds Bioscience's stock surged after positive results from its Phase 1 study. The company plans to advance to Phase 2.
The positive results from the Phase 1 study and the company's plans to advance to Phase 2 are likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100